Get the Weekly Intelligence Brief — top committee picks every Sunday.
EXEL · NASDAQ · STOCK

Exelixis

Healthcare Updated August 08, 2026
$54.10
52W $33.76 – $57.57
67/100
$13.59B
16.4
0.42
AI Committee Verdict
Buy
67/100
Conviction: High · 75% agreement · 4 analysts
+6.4%
-24.8%
0.26:1
High
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is EXEL Bullish or Bearish?

Bullish. Innellis AI committee rates Exelixis (EXEL) Buy with a composite score of 67/100 , based on 4 analysts with 75% agreement. Last updated August 08, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +8.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -11.75 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.

Bull & Bear Case

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.27 across 18 articles, 14d) — News
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 08, 2026
Overall Committee Score
67/100
Agreement
75%
Analysts
4
Conviction
High
Sector Rank
Top 14%
of 95 Healthcare peers
Growth Analyst bullish
82 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 18 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 66.0 to 66.8.

Analyst-level changes:
  • Growth Analyst: score 72->82 (+10).
  • News Analyst: +1 bullish signal(s).
  • Risk Analyst abstained (was bullish at 80).
  • Value Analyst abstained (was neutral at 59).

Comparing 2026-08-07 to 2026-08-08 (1 day apart).

Technical Analysis

RSI (14)
45.7
Neutral
MACD Histogram
-0.346
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$40.67
Resistance
$57.55
Bollinger %B
0.21
Inside Bands
Price vs Moving Averages
EMA 9
$54.78 Below
EMA 21
$54.97 Below
EMA 50
$53.60 Above
EMA 200
$47.38 Above

Fundamental Analysis

Valuation
68
Growth
85
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 16.4×
P/B Ratio 7.36×
PEG Ratio 0.31
Dividend Yield 0.00%
52W High $57.57
52W Low $33.76
Quality & Growth
ROE 3620.8%
ROA 2751.2%
Gross Margin 9648.3%
Operating Margin 3988.3%
Revenue Growth YoY
Debt / Equity 0.09
AI Fundamental Assessment
P/E ratio of 16.4 (inexpensive relative to a 15-40x range); Price-to-book of 7.4x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 36.2%; Return on assets of 27.5%; Net margin of 35.3%; Gross margin of 96.5%; Current ratio of 3.46 (healthy short-term liquidity); Debt-to-equity of 0.09; Free cash flow per share is positive (5.70); Most recent quarter beat estimates by 13.5%; 5 consecutive earnings beats; EPS growth accelerating (-10.2% -> +15.2% QoQ); Average YoY EPS growth of 40.0%; Analyst estimates falling over recent quarters
Get the Full EXEL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore EXEL Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime